Financials

Financials — What the Numbers Say

Tenet has spent the last five years rebuilding itself from a $15B-debt, single-digit-margin acute-care chain into a higher-margin operator with an outsized ambulatory engine. FY2025 revenue was $21.3B, but the right number to anchor on is EBITDA of $4.1B at a 19.3% margin — the cleanest measure of underlying profitability after the FY2024 divestiture noise washes out. Free cash flow of $2.5B in FY2025 is the highest in the company's history and converted at 180% of net income. Net debt has fallen to $10.3B (2.5x EBITDA) from a peak of 7.9x in 2015 — leverage is no longer the reason to avoid this name. Buybacks reduced share count by 16% over five years. The stock trades at 12.8x earnings, 7.9x EV/EBITDA, and 6.8x FCF at the FY2025 close — between value-stressed CYH/UHS and premium HCA. The single financial metric to watch right now is Hospital Operations EBITDA growth ex-divestitures — that is what proves the rerating is durable rather than a 2024 sugar-high.

Headline KPIs

How to read this page. Revenue is the top line. Operating income and EBITDA (earnings before interest, taxes, depreciation and amortization) measure profit before financial structure. Free cash flow is operating cash minus capex — the cash management can actually use. Net debt / EBITDA tells you how many years of profit it would take to repay debt; for hospital operators, anything under 4.0x is healthy and 2.5x is below average. ROIC (return on invested capital) measures dollars of after-tax operating profit per dollar of capital deployed — for a US for-profit hospital, double-digit ROIC is good.

Revenue, Margins, and Earnings Power

Tenet's revenue chart tells two stories on one timeline. The 2013–2020 era — built around the Vanguard merger and large hospital footprint — produced revenue near $18–20B with operating margins stuck in a 5–8% band. The post-2020 period, after USPI was scaled and underperforming hospitals divested, shows margins stepping up to a sustainably double-digit level.

The FY2024 spike on operating income and EBITDA is a divestiture gain, not earnings power. The honest signal is the sustained step-up from 2020 onward: EBITDA went from $2.2B in 2019 to $3.5B in 2021 and now $4.1B in 2025, a 15%+ CAGR through a period of essentially flat hospital revenue — almost all the gain is mix shift toward USPI ambulatory and pricing/cost discipline in Hospital Operations.

Gross margin has crept up from ~36% to ~41% as ambulatory revenue (which carries higher contribution margins) replaces low-acuity hospital admissions. Operating margin and EBITDA margin doubled from the 2015–2017 trough — that is the durable change. Net margin still bounces around because of two below-the-line items: interest expense (~$800M annually on $13B of debt) and minority interest (USPI hospitals/ASCs have meaningful non-controlling interests, which is why "consolidated" net income is materially higher than net income to Tenet shareholders).

Recent quarters confirm the run-rate: revenue around $5.3–5.5B per quarter and operating income around $770–890M in clean quarters. Q1 FY26 op income of $1,245M includes another modest divestiture gain (SC hospitals, March 2026). Reported Q1 FY26 EPS of $4.82 beat the $4.21 consensus and management raised FY2026 EPS guidance to $16.38–$18.68, which would imply 5–20% earnings growth on a high FY2025 base.

Cash Flow and Earnings Quality

The earnings-quality question for Tenet has historically been the same: do the reported profits become cash? For most of the 2010s the answer was no — high D&A, working-capital absorption, and constant capex on a 60+ hospital footprint meant operating cash flow swallowed most of the GAAP profits. That story flipped in 2020 and has held since.

Free cash flow = operating cash flow minus capital expenditure. It is the cash management can use to repay debt, buy back stock, pay dividends, or make acquisitions — without raising new capital.

Three things stand out:

1. FY2020 was inflated by COVID provider relief and CARES Act payment timing (large positive working-capital swing plus deferred payroll tax). That $2.9B FCF is not a fair baseline.
2. FY2025 FCF of $2.5B is the cleanest peak. Operating cash flow of $3.5B less capex of $1.0B leaves a $2.5B prize, and net income of $2.4B converts at >100%.
3. FY2024's smaller FCF ($1.1B) is misleading the other way — Tenet pre-paid taxes on the divestiture gains, suppressing operating cash flow that year, and the gain itself was non-cash (it sat in operating income but the cash showed up in investing).

The reader's takeaway: FY2025 is the first year in Tenet's modern history where reported profits, operating cash, and free cash all line up at high levels. There is no longer a meaningful gap between accounting earnings and cash earnings — and that is the single biggest structural change behind the rerating.

Balance Sheet and Financial Resilience

Tenet was, for most of the post-Vanguard era, a balance-sheet stress story. Total debt north of $15B, EBITDA below $2.5B, and shareholders' equity at one point negative. The chart below is the single most important picture on this page.

The red line collapsing from ~8x to ~2.5x over a decade is the deleveraging story. The FY2024 reading of 1.56x is artificially low because it divides through divestiture-boosted EBITDA; on a clean FY2025 basis, leverage is 2.5x — still meaningfully below the 4–6x range of the prior decade.

Three resilience reads. Liquidity: $2.9B cash plus an undrawn revolver and 1.76x current ratio leaves Tenet able to cover any near-term debt maturity from the balance sheet. Coverage: EBITDA covers interest 5.0x — comfortable for a B+/BB-rated hospital operator and a step-change from 1.8x in FY2017. Flexibility: with leverage near 2.5x and an investment-grade-adjacent profile, Tenet now has optionality for either accelerated buybacks, USPI bolt-on M&A, or a small acquisition.

The remaining structural risk is goodwill and intangibles of $12.5B against tangible book of negative $3.6B — meaning if anything went wrong with USPI's cash-generation profile, there is no asset cushion. That is why the cash-flow trend is so important: as long as USPI keeps producing, the goodwill is "supported"; if it stops, Tenet would be back in a stress scenario.

Returns, Reinvestment, and Capital Allocation

The case that Tenet is creating real value (rather than just inflating the headline through buybacks) rests on the return-on-capital chart. Here is what dollars of capital are actually earning.

ROIC = after-tax operating profit / invested capital. ROE = net income / equity. ROA = net income / total assets. ROE looks high partly because equity was small or briefly negative through 2017–2020 — denominator effect, not operating quality. ROIC is the clean metric here.

ROIC of 11.4% in FY2025 is genuinely good for a hospital operator (the long-term industry average sits in mid-single digits). It is also above Tenet's own cost of capital, which is roughly 8–9% for a company with this leverage and beta. The 18.3% reading in FY2024 was divestiture-inflated — strip out the gains and FY2024 ROIC was ~9–10%, broadly continuous with FY2025.

The mix has tilted hard toward shareholder returns. Buybacks went from zero through 2020 to $1.4B in FY2025 — the largest in company history and roughly equal to that year's net income. Acquisitions remain modest bolt-ons rather than transformational deals. Capex has crept up to $1.0B (4.7% of revenue), funding USPI center build-outs.

Diluted share count fell from 106.8M in FY2021 to 90.2M in FY2025 — a 15.5% reduction, all while the stock price more than doubled. That is the textbook definition of intelligent capital return: returning capital when the leverage allowed it and when the stock was below subsequent fair value. Per-share EPS in FY2025 of $15.49 is roughly double what the company has reported in any clean year.

Segment and Unit Economics

The segment file in data/financials/segment.json was not retrievable in this run. From the FY2025 10-K and management's reporting, Tenet operates two reportable segments — Hospital Operations & Services (acute-care hospitals + ancillary services) and Ambulatory Care (USPI: 500+ surgical centers, surgical hospitals, and imaging centers). The economic split, based on company disclosures referenced in upstream research, is approximately:

The pattern that matters for the equity story: Ambulatory Care produces ~21% of revenue but close to 45% of segment EBITDA, at margins more than 2.5x the Hospital Operations segment. Every incremental dollar Tenet rotates from low-acuity hospital admissions into high-acuity ambulatory cases lifts blended margin, and that is exactly what management has been doing for five years. The segment economics also explain why peer pure-play ambulatory operators like SGRY trade at ~9.4x EV/EBITDA versus stressed acute-care peers at 5–6x — Tenet's EV multiple should be a weighted average, and it is.

Note: these are estimated splits from management commentary in upstream research files; the run's segment.json did not return values, so the precision is limited. The directional point — USPI does most of the heavy lifting on profitability — is well-corroborated across upstream agents.

Valuation and Market Expectations

The right valuation question is not "is THC cheap?" but "what is the market pricing this business at, given growth, margin, leverage and cash conversion?" Three multiples answer that.

The negative-P/E years (2015, 2016, 2017, 2019) are when Tenet had GAAP losses; meaningful only as a marker that the multiple was undefined. The clean read is the EV/EBITDA line, which sat in the 7.5–11.0x band for a decade and is now at 7.9x — middle of the historical range. The 4.1x reading in FY2024 is divestiture-inflated EBITDA again — discount it.

Reading the scenarios: Multiplying FY2027E EBITDA (in $B) by an EV/EBITDA multiple gives EV; subtract net debt of ~$10.3B to get equity; divide by ~90M shares for an indicative price. Scenarios use round numbers — they are valuation scaffolds, not precision forecasts.

The current price of roughly $187 sits at the midpoint of the base case — neither obviously cheap nor obviously expensive. Sell-side targets cluster in the $210–$260 range (consensus around $240, MarketBeat 19 Buy / 3 Hold / 1 Strong Buy), suggesting the Street is closer to the base/bull line. The bear case is real if FY2026 admissions mix (flagged as soft in Q1 FY26) keeps deteriorating; the bull case requires continued ambulatory mix shift plus another round of buybacks at sub-$200.

Peer Financial Comparison

Choose the right peer for the question: HCA is the scale benchmark, UHS and CYH are direct hospital comps, SGRY is the only listed ambulatory pure-play, and ACHC is a stressed specialty operator.

The peer gap that matters. Tenet earns a higher EBITDA margin (19.3%) than UHS (15.0%) and CYH (15.3%) and is closer to HCA's premium 20.5%. Yet Tenet trades at 7.9x EV/EBITDA — one full turn below HCA's 9.2x and roughly one turn above the stressed UHS/CYH multiples. The market is pricing Tenet as "almost-HCA" but not quite: the discount makes sense if you doubt the durability of USPI's margin contribution, and looks too wide if you trust it.

The scatter shows the relationship cleanly: hospital operators get paid for margin and scale. Tenet is the second-most profitable operator in the peer set after HCA, sized between UHS and HCA, and priced slightly below where its margin alone would warrant. There is room for a half-turn rerating if FY2026 numbers hold, but no obvious value gap that lasts beyond that.

What to Watch in the Financials

Binder Error: Set operations can only apply to expressions with the same number of result columns

What the financials confirm. Margins have stepped up to a sustainably higher level. Cash conversion is now strong. Leverage is fixed. Returns on capital are above cost of capital. Capital is being returned to shareholders intelligently. The business has rebuilt its right to a "normal" multiple.

What they contradict. The bull narrative of "USPI compounding" is not yet visible in segment-level financials with the granularity an analyst would like — segment data was not available in this run, and the picture must be triangulated from full-year EBITDA and management commentary. Hospital-Operations growth, ex-divestiture, looks closer to flat than growing; if USPI ever decelerates, blended growth disappears.

The first financial metric to watch is Hospital Operations EBITDA growth ex-divestitures. If it prints at +5% or better in FY2026 — proving the legacy hospital book is genuinely earning more, not just shrinking gracefully — Tenet earns a HCA-style 9.0x+ multiple and the stock has 15-25% upside from here. If it goes flat or negative, the bull case rests on USPI alone, the multiple compresses to UHS levels, and the stock has 10-15% downside. Everything else on this page is essentially a corollary of that single line.